Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2006

01-12-2006 | Research Articles

Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia

Authors: Antonio Jimeno, Alberto Arcediano, Susana Bezares, María Luz Amador, Lucía González-Cortijo, Eva Ciruelos, Luis Robles, Daniel Castellano, Luis Paz-Ares, Carlos Lumbreras, Javier Hornedo, Hernán Cortés-Funes

Published in: Clinical and Translational Oncology | Issue 12/2006

Login to get access
Metadata
Title
Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia
Authors
Antonio Jimeno
Alberto Arcediano
Susana Bezares
María Luz Amador
Lucía González-Cortijo
Eva Ciruelos
Luis Robles
Daniel Castellano
Luis Paz-Ares
Carlos Lumbreras
Javier Hornedo
Hernán Cortés-Funes
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 12/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0152-3

Other articles of this Issue 12/2006

Clinical and Translational Oncology 12/2006 Go to the issue

Editorial

It is about time that spain launches a National Cancer Act?

Educational Series

New potential therapeutic targets to combat epithelial tumor invasion

News and Views

Comprehensive Cancer Centers: toward concentration of experience

Research Articles

Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain

Case Reports

Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern

Educational Series

Viral gene therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits